Cancer NetworkOriginal article
<![CDATA[FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC]]>
NDA FilingUGN-103Positive
AI Analysis
Summary
The FDA accepted the NDA for UGN-103 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer and assigned a PDUFA date of June 14, 2027.
Outcome Details
FDA accepted the NDA for UGN-103 and assigned a PDUFA date of June 14, 2027.
Importance:6/10
Sentiment:
0.40
NDA acceptancePDUFANMIBCbladder canceroncologyFDA
Read the original article
Published by Cancer Network on October 19, 2026 2:30 PM